

**DESIGN, DEVELOPMENT & EVALUATION OF SELF EMULSIFYING DRUG
DELIVERY SYSTEM OF AMLODIPINE**Jograna M.B.^{1*}, Bhosale A.V.² and Kakade S.S.¹¹P.D.E.A.'s S. U. College of Pharmaceutical Sciences and Research Center, Kharadi, Pune.²P.D.E.A.'s S.G.R.S. College of Pharmacy, Saswad, Tal-Purander, Dist-Pune.***Corresponding Author: Jograna M.B.**

P.D.E.A.'s S. U. College of Pharmaceutical Sciences and Research Center, Kharadi, Pune.

Article Received on 03/08/2019

Article Revised on 29/08/2019

Article Accepted on 19/09/2019

ABSTRACT

Amlodipine (3-ethyl-5-methyl-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-1, 4-dihydro-6-methyl-3,5-pyridinedicarboxylate) is used to treat high blood pressure and chest pain (angina). Amlodipine is given orally (5mg or 10mg daily) with peak plasma concentration occurring after 6-12 hrs, and has oral bioavailability of 60-65% only due to extensive hepatic metabolism. Amlodipine belonging to the 1, 4-dihydropyridine class are photosensitive since light catalyzes their oxidation to pyridine derivatives, lacking any therapeutic effect. From a pharmaceutical point of view, dry emulsions are attractive because they are physically and microbiologically stable formulations, which are easy to administer in the form of powders as capsules and tablets. Hence a novel a solid form of lipid-based self-emulsifying drug delivery system (SEDDS) is formulated by spray drying liquid SEDDS with an inert solid carrier to improve the photostability and oral bioavailability of poorly water-soluble drug amlodipine. Solid self-emulsifying drug delivery systems of amlodipine were prepared by using different oils, surfactants and co-surfactants and evaluated for its *in vitro* performance. Optimized, Solid amlodipine SEDD composed of amlodipine (5 mg), Labrafil M1944 CS (30%), S_{mix} (70%) and Maltodextrin (10 gm). The globule size distribution of this formulation was within appropriate range (0.600–0.900 μm). *In vitro* release in 0.1 N HCl revealed a prompt release within 5 minute up to 90%. SEDDS of amlodipine showed a significant increase in photostability and oral bioavailability of amlodipine.

KEYWORDS: Amlodipine, Solid self-emulsifying drug delivery system (SEDDS), Bioavailability, Photostability.**1. INTRODUCTION**

Dissolution rate is the limiting factor for the drug absorption for both class II and class IV drugs according to the biopharmaceutics classification system.^[1] Emulsion has been reported to be one of the efficient methods to improve the dissolution rate and increase bioavailability of poorly water-soluble drugs.^[2] However, the instability of an emulsion such as creaming, flocculation, coalescence, and phase separation was often mentioned.

In recent years, much attention has been paid to self-emulsifying drug delivery systems (SEDDS), which have shown lots of reasonable successes in improving oral bioavailability of poorly soluble drugs.^[3,4,5,6] SEDDS are usually composed of a mixture of oil and surfactant or cosurfactant and are capable of forming fine oil-in-water emulsions upon gentle agitation provided by the GIT motion. After oral administration, SEDDS can maintain the poorly soluble drugs dissolved in the fine oil droplets when transiting through the GIT. However, traditional preparations of SEDDS are usually prepared in the liquid state. So the liquid SEDDS are generally enclosed by soft or hard capsules to facilitate oral administration but

it produce some disadvantages, such as high production costs, low drug incompatibility and stability, drugs leakage and precipitation, capsule, ageing. Then incorporation of liquid SEDDS into a solid dosage form is compelling and desirable, and some solid self-emulsifying (SE) dosage forms have been initially explored, such as SE tablet and pellets.^[7]

Amlodipine is a dihydropyridine calcium antagonist and its besylate salt (Norvasc® manufactured by Pfizer) is one of the most frequently prescribed antihypertensive drugs in the world.^[8] In present study, amlodipine was used as a model drug with poor aqueous solubility and photostability. It has been reported that the dissolution rate of amlodipine is low due to its limited solubility in water.^[9] Amlodipine is also known as photosensitive since light catalyzes oxidation of amlodipine to pyridine derivatives that are therapeutically ineffective.^[10,11,12]

The purpose of this study was to develop spray-dried DE of amlodipine, without utilizing any milling method or chemical modification, in order to enhance the bioavailability and photostability of amlodipine. We used maltodextrin as a matrix material since the formulation

with maltodextrin derivative has been reported to improve the solubility, dissolution, absorption and photostability of certain types of drugs^[12,13] and were proven to be suitable for solid dosage form due to their free-flowing property.

2. MATERIALS AND METHODS

Amlodipine was received as a gift sample from Zydus Cadila, Goa., India, Capmul PG-8 was received as a gift sample from Abitec Corporation (US). Labrafil M 1944 CS and Labrafil M 2125 CS were received as a gift sample from Gattefosse India Pvt Ltd (Mumbai, India). Oleic acid AR, Olive Oil AR, Sesame oil AR, Isopropyl myristate AR, Tween 60 AR, Tween 20 AR, Span 80 AR, Span 20 AR, PEG 600 AR, PEG 400 AR, PEG 200 AR, Carbitol AR, Ethanol AR were purchased from Research lab (Mumbai, India). Methanol (HPLC Grade) was purchased from SISCO Research lab pvt ltd, Mumbai.

2.1 Screening of Excipients

2.1.1 Solubility study^[13,14,15]

The solubility of amlodipine in various oils, surfactants, and co-surfactants was measured, respectively. An excess amount of amlodipine was added into 2 ml of each of the selected oils, surfactants, co-surfactants and distilled water in 5-ml stoppered vials separately, and mixed by vortexing. The mixture vials were then kept at $25 \pm 1.0^\circ \text{C}$ in an isothermal shaker for 72 h to reach equilibrium. The equilibrated samples were removed from shaker and centrifuged at 3000 rpm for 15 min. The supernatant was taken and filtered through a $0.45 \mu\text{m}$ membrane filter. The concentration of amlodipine was determined in oils, surfactants, co-surfactants and water using UV- spectrophotometer at 360 nm and results were reported in section 3.1.1.

2.1.2. Preliminary screening of surfactants

Emulsification ability of various surfactants was screened.^[16] Briefly, 300 mg of surfactant was added to 300 mg of the selected oily phase. The mixture was gently heated at $45\text{--}60^\circ\text{C}$ for homogenizing the components. The isotropic mixture, 50 mg, was accurately weighed and diluted with double distilled water to 50 ml to yield fine emulsion. The ease of formation of emulsions was monitored by noting the number of volumetric flask inversions required to give uniform emulsion. The resulting emulsions were observed visually for the relative turbidity. The emulsions were allowed to stand for 2 h and their transmittance was assessed at 360 nm by UV-spectrophotometer (UV-1800 Shimadzu) using double distilled water as blank and results were reported in section 3.1.2.

2.1.3. Preliminary screening of co-surfactants

The turbidimetric method was used to assess relative efficacy of the co-surfactant to improve the nanoemulsification ability of the surfactants and also to select best co-surfactant from the large pool of co-

surfactants available for peroral delivery.^[14,15] Surfactant, 0.2 gm was mixed with 0.1 gm of co-surfactant. Labrafil M 1944 CS, 0.3 gm, was added to this mixture and the mixture was homogenized with the aid of the gentle heat ($45\text{--}60^\circ\text{C}$). The isotropic mixture, 50 mg, was accurately weighed and diluted to 50 ml with double distilled water to yield fine emulsion. The ease of formation of emulsions was noted by noting the number of flask inversions required to give uniform emulsion. The resulting emulsions were observed visually for the relative turbidity. The emulsions were allowed to stand for 2 h and their transmittance was measured at 360 nm by UV-spectrophotometer (UV-1800 Shimadzu) using double distilled water as blank. As the ratio of co-surfactants to surfactant/s is the same, the turbidity of resulting nanoemulsions will help in assessing the relative efficacy of the co-surfactants to improve the nanoemulsification ability of surfactant/s and results were reported in section 3.1.3.

2.2. Drug – Excipients Compatibility Study

The Drug – Excipients Compatibility Studies were performed in order to confirm the drug- excipients compatibility. This study mainly include DSC given below, The DSC study was carried out for pure amlodipine, Tween 20, PEG 400, Labrafil M 1944 CS & physical mixtures of all excipients that were expected to be used in the development of formulation like oil phase, emulsifier, surfactant and co-surfactant etc. The DSC patterns were recorded on a METTLER TOLDO DSC1 STAR SYSTEM. Each sample (2-4mg) was heated in crimped aluminum pans at a scanning rate of $10^\circ\text{C}/\text{min}$ in an atmosphere of nitrogen using the range of $30\text{--}400^\circ\text{C}$. The temperature calibrations were performed periodically using indium as a standard and thermograms obtained were observed for any interaction. The results were reported in section 3.2 and DSC curves were shown in Figure 10.9.

2.3. Construction of Pseudo-ternary phase diagram.^[19]

A pseudo-ternary phase diagram was constructed by titration of four component mixtures of oil, surfactant and co-surfactant with water at room temperature. After equilibrium, the mixture was visually observed. The generated sample which was clear or slightly bluish in appearance was determined as microemulsion.

On the basis of the solubility studies of drug, select the oil phase, surfactants and co-surfactants. Water was used as an aqueous phase for the construction of phase diagrams. Surfactant : co-surfactant (S_{mix}) are mixed in different weight ratios 1:0, 0.5:1(1:2), 1:1, 1:0.5 (2:1), 3:1. These S_{mix} ratios were chosen in increasing concentration of surfactant with respect to co-surfactant and increasing concentration of co-surfactant with respect to surfactant for detailed study of the phase diagrams. For each phase diagram, oil and specific S_{mix} ratio was mixed thoroughly in different weight ratios from 1:9 to 9:1 in different glass vials. Sixteen different

combinations of oil and Smix were made so that maximum ratios were covered for the study to delineate the boundaries of phases precisely formed in the phase diagrams. Pseudo ternary phase diagrams were developed using aqueous titration method. Slow titration with aqueous phase was done to each weight ratio of oil and Smix and visual observation was carried out for transparent and easily flowable o/w microemulsions. The mixture was visually examined for transparency. After equilibrium was reached, the mixtures were further titrated with aliquots of distilled water until they showed the turbidity. Clear and isotropic samples were deemed to be within the microemulsion region. No attempts were made to completely identify the other regions of the phase diagrams. Based on the results, appropriate percentage of oil, surfactant and co-surfactant was selected, correlated in the phase diagram and were used for preparation of SEDDS containing amlodipine. All studies were repeated thrice, with similar observations being made between repeats and results of phase diagram were reported in section 3.3.

2.4 Selection of Formulation from Pseudo Ternary Phase Diagram^[19]

From each phase diagram, constructed, different formulations were selected from micro-emulsion region it is reported in section 3.4, so that drug could be incorporated into the oil phase on the following bases.

- The oil concentration should be such that it solubilizes the drug (single dose) completely depending on the solubility of the drug in the oil. 5 mg of amlodipine will dissolve easily in 1 ml of oil.
- To check if there was any effect of drug on the phase behavior and microemulsion area of the phase diagram.
- The minimum concentration of the S_{mix} used for that amount of oil was taken.
- For convenience purposes, 1ml was selected as the microemulsion formulation, so that it can be increased or decreased as per the requirement in the proportions. Selected formulations were subjected to different thermodynamic stability and Dispersibility tests.

Selected formulations were subjected to different thermodynamic stability and dispensability tests.

2.4.1. Thermodynamic stability studies

2.4.1.1. Heating cooling cycle

Six cycles between refrigerator temperature 4°C and 45°C with storage at each temperature of not less than 48h was studied. Those formulations, which were stable at these temperatures, were subjected to centrifugation test.

2.4.1.2. Centrifugation

Passed formulations were centrifuged at 3500 rpm for 30 min. Those formulations that did not show any phase separation were taken for the freeze thaw stress test.

2.4.1.3. Freeze thaw cycle

Three freeze thaw cycles between -21°C and +25°C with storage at each temperature for not less than 48 h was done for the formulations.

Those formulations, which passed these thermodynamic stress tests, were further taken for the dispersibility test for assessing the efficiency of self-emulsification.

2.4.2. Dispersibility test

The efficiency of self-emulsification of oral microemulsion was assessed using a standard USP dissolution apparatus 2 (Disso TDT 08L, Electrolab). One milliliter of each formulation was added to 500 mL of water at 37±0.5°C. A standard stainless steel dissolution paddle rotating at 50 rpm provided gentle agitation. The *in-vitro* performance of the formulations was visually assessed using the following grading system:

Grade A: Rapidly forming (within 1 min) nanoemulsion, having a clear or bluish appearance.

Grade B: Rapidly forming, slightly less clear emulsion, having a bluish white appearance.

Grade C: Fine milky emulsion that formed within 2 min.

Grade D: Dull, grayish white emulsion having slightly oily appearance that is slow to emulsify (longer than 2min).

Grade E: Formulation, exhibiting either poor or minimal emulsification with large oil globules present on the surface.

Those formulations that passed the thermodynamic stability and also dispersibility test in Grade A, Grade B and Grade C was selected for further studies. The results were reported in section 10.6 (Table 3.6 & 3.7).

2.5. Preparation of Liquid SEDDS Formulations^[16]

The formulations were prepared by dissolving the formulation amount of amlodipine (5 mg/mL) in the mixture of surfactant, oil and co-surfactant (Table 2.1). Tween 20, Labrafil M 1944 CS, Polyethyleneglycol 400 (PEG 400), and amlodipine were accurately weighed and transferred into a borosilicate glass vial. Using magnetic stirrer, the ingredients were mixed for 10 min at 60–65°C until a yellowish transparent formulation was attained. Amlodipine SEDDS formulations were then allowed to cool to room temperature before they were used in subsequent studies.

Table 2.1: Data for Preparation of Liquid SEDDS Formulations.

Ingredients	Group I (S_{mix} 2:1)			Group II (S_{mix} 3:1)		
	A	B	C	D	E	F
Amlodipine (gm)	0.005	0.005	0.005	0.005	0.005	0.005
Labrafil M 1944 CS (% w/w)	20	25	30	20	25	30
S_{mix} (% w/w)	80	75	70	80	75	70

Where S_{mix} is Tween 20 and PEG 400

2.6. Evaluation of Liquid SEDDS Formulations

2.6.1. Determination of emulsification time^[13]

The emulsification time of SEDDS was determined according to United State Pharmacopeia USP dissolution apparatus II (Disso TDT 08L, Electrolab). In brief, 0.5 mL of each formulation (Table 9.1) was added drop wise to 500mL of purified water at 37°C. Gentle agitation was provided by a standard stainless steel dissolution paddle rotating at 50 rpm. It was reported in section 3.6.1.

2.6.2. Turbidimetric evaluation^[20]

Self-emulsifying system (0.2 mL) was added to 0.1 mol L⁻¹ hydrochloric acid (150 mL) under continuous stirring (50 rpm) on a magnetic plate (Remi 1-MLH) at ambient temperature, and the increase in turbidity was measured until equilibrium was achieved using a turbidimeter (Digital Nephlo-Turbidity Meter 132, Systronics, India) and it was reported in section 3.6.2.

2.6.3. Drug Content^[20]

Amlodipine from preweighed SEDDS was extracted by dissolving in 25 mL methanol. Amlodipine content in the methanolic extract was analyzed UV-spectrophotometrically (UV-1800 Shimadzu) at 360 nm, against the standard methanolic solution of amlodipine and it was reported in section 3.6.3.

2.6.4. Globule size analysis^[13,20]

Droplet size distribution of SEDDS diluted with water was determined using a photon correlation spectrometer (Nanoz3-90, Malvern Ltd., UK) based on the laser light scattering phenomenon. Samples were diluted 200 times with purified water. Diluted samples were directly placed into the module and measurements were made in triplicate after 2-min stirring. Droplet size was calculated from the volume size distribution and it is reported in section 3.6.4.

2.6.5. Drug release studies^[13]

Drug release studies from SEDDS were performed using USP dissolution apparatus II (Disso TDT 08L, Electrolab) with 500 mL of 0.1N HCl as medium at 37±0.5°C. The speed of the paddle was adjusted to 100 rpm. 1 mL of the formulation was (5 mg of drug) directly introduced into the medium and an aliquot (2 mL) of sample was collected at designated times and analyzed for the content of amlodipine by UV-spectrophotometer at 360 nm. An equivalent volume (2 mL) of fresh dissolution medium was added to compensate for the loss due to sampling and results of drug release study were reported in section 3.6.5.

2.7 Preparation of solid SEDDS^[16]

Maltodextrin was dissolved in 100 ml distilled water by magnetic stirring. The liquid SEDDS was then added with constant stirring, and the solution was kept at 50°C for 10 min to obtain a good o/w emulsion. The emulsion was spray dried with a Labultima spray dryer (LU 222 ADVANACED) apparatus. Conditions and parameter for spray drier are shown in Table 2.2.

Table 2.2: Data for Spray Drying Parameters.

Sr. No.	Parameters	Condition at which the formulations were prepared
1	Inlet temperature	120°C
2	Outlet temperature	100°C
3	Feed pump	2.5 mL/min
4	Aspirator Speed	40mmWC
5	Vacuum	25 PSI
6	Cycle time	45 min

Table 2.3: Data for Preparation of Solid SEDDS Formulations.

Ingredients	Group I (S_{mix} 2:1)	Group II (S_{mix} 3:1)
	F ₁	F ₂
Maltodextrin (g)	10	10
Liquid SEDDS (g)	10	10
Water (mL)	100	100

2.8. Evaluation of Solid SEDDS Formulations

2.8.1. Reconstitution properties of solid SEDDS^[16]

2.8.1.1. Reconstitution

Solid SEDDS (100mg) prepared was dispersed with 10 ml distilled water, respectively, by vortex mixing (30s), and then incubated for 30 min at 25°C and the results of reconstitution was reported in section 3.8.1.

2.8.1.2. Droplet size of reconstituted emulsions

The average droplet size, size distribution emulsions from solid SEDDS were assessed by photon correlation spectrometer (Nanoz3-90, Malvern Ltd., UK) and results of droplet size was reported in section 3.8.1.

2.8.2. Drug Content^[21]

Amlodipine from preweighed solid SEDDS was extracted by dissolving in 25 mL methanol. Amlodipine content in the methanolic extract was analyzed UV-spectrophotometrically (UV-1800 Shimadzu) at 360 nm, against the standard methanolic solution of amlodipine and results of drug content was reported in section 3.8.2.

2.8.3. Drug release study^[17]

Drug release studies from solid SEDDS were performed using USP dissolution apparatus II (Disso TDT 08L, Electrolab) with 500 ml of 0.1N HCl pH 1.2 as a medium at $37 \pm 0.5^\circ\text{C}$. The speed of the paddle was adjusted to 100 rpm. Amlodipine-loaded solid SEDDS (equivalent to 5 mg of amlodipine) were placed in a dissolution tester. At predetermined time intervals an aliquot (2 ml) of the sample was collected, filtered and analyzed for the content of amlodipine by UV-spectrophotometer (UV-1800 Shimadzu) as mentioned above. An equivalent volume (2 ml) of fresh dissolution medium was added to compensate for the loss due to sampling and results of drug release study was reported in section 3.8.3.

2.8.4. Morphological analysis of solid SEDDS

The outer macroscopic structure of the solid SEDDS was investigated by Scanning Electron Microscope (SEM) with a Scanning Electron Microscope (JEOL JSM- 6360, Japan), operating at 10 kV and results of SEM was reported in section 3.8.4.

2.8.5. Solid state characterization of solid SEDDS

2.8.5.1. DSC

The physical state of amlodipine in solid SEDDS was characterized by the differential scanning calorimetry thermogram analysis. The DSC patterns were recorded on a METTLER TOLIDO DSC1 STAR SYSTEM. Each sample (2-4mg) was heated in crimped aluminum pans at a scanning rate of $10^\circ\text{C}/\text{min}$ in an atmosphere of nitrogen using the range of $30\text{-}400^\circ\text{C}$. The temperature calibrations were performed periodically using indium as a standard. The DSC curves are shown in Figure 10.17. and a result of solid state characterization was reported in section 3.8.5.1.

2.9 Photostability study^[16,22]

2.9.1. Preparation of sample for irradiation test

All samples were passed through a sieve no. 40 to obtain fine powders with uniform particle sizes before irradiation tests.

2.9.2. Irradiation by fluorescent lamp

The irradiation test was employed utilizing a fluorescent lamp (FL-15 Watt, vacuum tube). Each sample of pure amlodipine powder, solid SEDDS of amlodipine was placed and spread uniformly as a thin film on an aluminum foil. The fine powders on the aluminum foil were discrete enough to allow for uniform irradiation. Irradiation was conducted inside a light cabinet (PLC-Controlled Photostability chamber 21CFR, Newtronic megalis) to protect samples from extraneous light. The accelerated irradiation test using this lamp was carried out at ambient temperature. Samples were assayed for their content of amlodipine prior to exposure and at 4, 8, 12 and 24 h. of continuous exposure using HPLC assay method.^[18] The obtained chromatograms at different times were shown in Figure 10.18 and 10.19.

3 RESULTS AND DISCUSSION

3.1. Screening of Excipients

3.1.1. Solubility study

The self-emulsifying formulations consisted of oil, surfactants, co-surfactants and drug should be clear and monophasic liquids at ambient temperature when introduced to aqueous phase and should have good solvent properties to allow presentation of the drug in solution. Solubility studies were aimed at identifying suitable oily phase and surfactant/s for the development of amlodipine SEDDS. Identifying the suitable oil, surfactant/co-surfactant having maximal solubilizing potential for drug under investigation is very important to achieve optimum drug loading.^[23,24] The solubility of amlodipine in various oily phases, surfactants and co-surfactant is reported in **Table 3.1** & **Figure 3.1**, **Table 3.2** & **Figure 3.2** and **Table 3.3** & **Figure 3.3** respectively.

The **Table 3.1** demonstrated that solubility of the lipophilic drug – amlodipine – was found to be highest in Labrafil M 2125 CS (Linoleoyl macrogol- 6 glycoside) followed by Isopropyl Myristate and Labrafil M 1944 CS (Oleoyl macrogol- 6 glycoside). Solubility of drug in these oils was significantly high than in Capmul PG-8 and Oleic acid. All the surfactants showed good solubility of the drug (**Table 3.2**). Among the surfactants tested in this study, Tween 20, a medium-length alkyl chain with HLB 16.7 was selected as appropriate surfactant because non-ionic surfactants are less toxic than ionic surfactants, has good biological acceptance; is powerful permeation enhancer, less affected by pH and ionic strength, and highest solubility of Amlodipine was obtained. Furthermore, Carbitol (Diethylene glycol monoethyl ether), polyethyleneglycol 400 (PEG 400) were selected as a co-surfactants because of their potential to solubilize the drug.^[25]

Table 3.1: Data for Solubility study of Amlodipine in Various Oils.

Sr No	Oil	*Solubility of Amlodipine (mg/ml) at 25°C
1	Olive Oil	7.53 ±5.21
2	Corn Oil	4.83 ±6.43
3	Sesame oil	8.73 ±2.74
4	oleic acid	6.16 ±7.24
5	Labrafil M 1944 CS	11.24 ±6.23
6	Isopropyl Myristate	13.83 ±4.40
7	Labrafil M 2125 CS	18 ±5.68
8	Capmul PG 8	9.2 ±5.23

*Represents mean ± S.D. (n = 3)




Figure 3.1: Solubility study of Amlodipine in Various Oily Phases.

Table 3.2: Data for Solubility study of Amlodipine in Various Surfactants.

Sr No	Surfactant	*Solubility of Amlodipine (mg/ml) at 25°C
1	Tween 20	110.92 ±6.74
2	Span 20	122.52 ±29.42
3	Tween 60	75.98 ±7.25
4	Span 80	64.5 ±22.33

=*Represents mean ± S.D. (n = 3)




Figure 3.2: Solubility study of Amlodipine in Various Surfactants.

Table 3.3: Data for Solubility study of Amlodipine in Various Co-Surfactants.

Sr No	Co-Surfactant	*Solubility of Amlodipine (mg/ml) at 25°C
1	Ethanol	170.32 ±5.04
2	PEG 200	209.14 ±5.75
3	PEG 400	235.64 ±5.39
4	PEG 600	168.25 ±4.49
7	Carbitol	310.87 ±8.6

* Represents mean ± S.D. (n = 3)




Figure 3.3:- Solubility study of Amlodipine in Various Co-Surfactants.

3.1.2. Preliminary screening of surfactants

Non-ionic surfactants are generally considered less toxic than ionic surfactants. They are usually accepted for oral ingestion. The surfactants were compared for their emulsification efficiencies using different oily phases. It has been reported that well formulated SEDDS is dispersed within seconds under gentle stirring conditions. Transmittance values of different mixtures are demonstrated in **Table 3.4**. From results it was inferred that the oily phase Labrafil M 1944 CS exhibited the highest emulsification efficiency with Tween 20, requiring only 5 flask inversions for homogenous emulsion formation. On the other hand, Labrafil M 2125 CS showed poor emulsification properties with Tween 20, requiring a minimum of 40 flask inversions. The aforementioned results suggested the use of Labrafil M 1944 CS as an oily phase with Tween 20 as a surfactant for further study.^[26]

Table 3.4: Data for Emulsification efficiency of surfactant.

Sr. No.	Oils	% Transmittance
		Tween 20
1.	Labrafil M 1944 CS	94
2.	Labrafil M 2125 CS	75
3.	Isopropyl Myristate	67

3.1.3. Preliminary screening of co-surfactants

Addition of a co-surfactant to the surfactant-containing formulation was reported to improve dispersibility and drug absorption from the formulation. In view of current investigation, two co-surfactants, polyethyleneglycol 400, Transcutol-P, were compared for ease of emulsification. As reported in **Table 3.5**, the Labrafil M 1944 CS exhibited good emulsification with both co-surfactants, i.e. PEG 400 showing maximum transmittance (96.5%) followed by Carbitol (92%).^[25]

Table 3.5: Data for Emulsification efficiency of Co-surfactant.

Sr. No.	Co-surfactants	% Transmittance Labrafil M 1944 CS
1.	Polyethyleneglycol 400	96.5
2.	Carbitol	92

Based on the results of preliminary screening, one distinct system was selected which was Labrafil M 1944 CS as oily phase, Tween 20 as surfactant, polyethyleneglycol 400 as co-surfactant for further studies.

3.2. Drug – Excipients Compatibility Study

Compatibility of drug and excipients can be determined by differential scanning calorimetry.




Figure 3.4:- DSC Spectra of Amlodipine and Excipients.

Endothermic peaks of Amlodipine at 208°C disappeared in the curves of Labrafil M 1944 CS + Amlodipine, Tween 20+ Amlodipine, PEG 400 + Amlodipine and combination drug & all these excipients. It might be explained as excipients inhibited the crystallization of Amlodipine, because oil, surfactant and co-surfactant produces the molecular dispersion of Amlodipine. According to DSC graph drug and excipients are compatible to each other^[16]

(shaded) the addition of great volumes of continuous phase allowed the clear system.

3.3. Construction of Pseudo ternary phase diagram

The consideration for screening formulation of SEDDS usually involves: the formulation composition should be simple, safe, and compatible; it should possess good solubility; a large efficient self-emulsification region which should be found in the pseudo-ternary phase diagram, and have efficient droplet size after forming microemulsion. Thus, pseudo-ternary phase diagrams were constructed to identify the self-emulsifying regions with maximum drug loading and to optimize the concentration of oil, surfactant and co-surfactant in the SEDDS formulations and to obtain transparent and stable O/W micro-emulsions.




Figure 3.5 A.

The shaded areas in the pseudo-ternary phase-diagrams shown in **Figure 3.5** represented the existence field of stable, clear and transparent O/W micro-emulsions containing Labrafil M1944 as oil and with the Tween 20: PEG 400 fixed mixing ratio, respectively. For any selected composition of surfactant and co-surfactant ratio from self emulsifying region of ternary phase diagram




Figure 3.5 B.




Figure 3.5 E.




Figure 3.5 C.




Figure 3.5 D.

Figure 10.10:- Pseudo-ternary phase diagrams of the formulations composed of Labrafil M 1944 CS as oil phase, Tween 20 and PEG 400 dispersed with distilled water at 37°C. The S_{mix} (Surfactant:Co-surfactant) ratios were as follows: For 3.5 A S_{mix} (1:0), 3.5 B S_{mix} (1:1), 3.5 C S_{mix} (1:2), 3.5 D S_{mix} (2:1) and 3.5 E S_{mix} (3:1)

Figure 3.5 (A-E) presented phase diagram of Labrafil M 1944 CS (oil)- S_{mix} (Tween 20 and Polyethylene glycol 400)- Water system having different S_{mix} ratio (1:0, 1:1, 1:2, 2:1, 3:1). It can be seen that these phase diagrams contained different areas of clear and isotropic microemulsion region.

It can be also seen that microemulsion region exists at S_{mix} ratio 1:0 (i.e. without co-surfactant). However, equal mixture of surfactant and co-surfactant decreases the microemulsion region (Fig 3.5 B). Increasing the concentration of surfactant (2:1) resulted in even larger area of microemulsion region (Fig 3.5 D). Further increasing surfactant concentration from 2:1 to 3:1 resulted in no influence on microemulsion region (Fig 3.5 E). The influence of concentration of co-surfactant on the microemulsion region was also seen by constructing the phase diagram in ratio of 1:2. It was seen that the region of microemulsion was decreased with increase in concentration of co-surfactant (Fig 3.5 C).

The existence of large or small microemulsion region depends on the capability of a particular surfactant or surfactant mixture to solubilize the oil phase. The extent of solubilization resulted in a greater area with clearer and homogenous solution. It was seen that when the surfactant (Tween 20) was used alone, the oil phase was solubilized to a lesser extent at higher concentration of surfactant implying that surfactant alone was not able to reduce the interfacial tension of oil droplet to a sufficiently low level and thus was not able to reduce the free energy of the system to an ultra low level desired to

produce microemulsions. When a co-surfactant was added, the interfacial tension was reduced to a very low level and very small free energy was achieved which helps in larger microemulsion region. With further increase in surfactant from 1:1 to 2:1 and 3:1 further drop in interfacial tension and free energy was achieved resulting in maximum region of microemulsion/ self-emulsifying formation. Thus, pseudo-ternary phase diagram for S_{mix} 2:1 and 3:1 were selected for the formation of drug loaded self emulsifying drug delivery system.

3.4. Selection of Formulation from Pseudo ternary Phase Diagram

It is well known that large amounts of surfactants cause GI irritation therefore, it is important to determine the surfactant concentration properly and use minimum concentration in the formulation. S. Shafiq *et al.* reported the basis of selecting different nanoemulsion or microemulsion formulations from the phase diagram, as hundreds of formulations can be prepared from nanoemulsion region of the diagram. From the data shown in different pseudo-ternary phase diagrams (Figs 3.5 D – 3.5 E), it was understood that oil could be solubilized up to the extent of 50% w/w. Therefore, from phase diagram (Figs 3.5 D – 3.5 E) different concentrations of oil, which formed nanoemulsions, were selected at a difference of 5% (20, 25, 30, 35, 40, 45 and 50%) so that maximum formulations could be prepared covering the nanoemulsion/ self emulsification area of the phase diagram (Tables 3.6 and 3.7). For each percentage of oil selected, only those formulations were taken from the phase diagram, which needed minimum concentration of S_{mix} . There was no sign of change in the phase behavior and nanoemulsion area of phase diagrams when Amlodipine (5 mg) was incorporated in the formulations, which was indicated as the formation and stability of nano- and microemulsions consisting of nonionic components is not affected by the pH and or ionic strength.^[26,27]

3.4.1. Thermodynamic stability studies

Nanoemulsions are thermodynamically stable systems and are formed at a particular concentration of oil,

surfactant and water, with no phase separation, creaming or cracking. It is the thermostability which differentiates nano- or microemulsion from emulsions that have kinetic stability and will eventually phase separate.^[133] Thus, the selected formulations were subjected to different thermodynamic stability testing by using heating cooling cycle, centrifugation and freeze thaw cycle stress tests. Those formulations, which passed thermodynamic stability tests, were taken for dispersibility test (Table 3.6 and 3.7).

Thus it was concluded that the efficiency of surfactant and co-surfactant mixture was unaffected after exposing to extreme conditions.

3.4.2. Dispersibility test

When infinite dilution is done to nanoemulsion formulation, there is every possibility of phase separation, leading to precipitation of a poorly soluble drug as nanoemulsions are formed at a particular concentration of oil, surfactant and water. For oral nanoemulsions the process of dilution by the GI fluids will result in the gradual desorption of surfactant located at the globule interface. The process is thermodynamically driven by the requirement of the surfactant to maintain an aqueous phase concentration equivalent to its CMC.^[27]

In the present study, we used distilled water as a dispersion medium because it is well reported that there is no significant difference in the nanoemulsions prepared using nonionic surfactants, dispersed in either water or simulated gastric or intestinal fluid.^[26] Formulations in Group I (Table 3.6) and Group II (Table 3.7) that passed dispersibility test in Grade A, B and C were taken for further study, as Grade A and B formulations will remain as nanoemulsions when dispersed in GIT. Formulation falling in Grade C could be recommended for self-emulsifying drug delivery formulation.

So from the study, total six formulations were selected for further study three from each group i.e. F_1 , F_2 , F_3 from Group I and F_1 , F_2 , F_3 from Group II.

Table 3.6: Data for Thermodynamic stability test of different formulations selected from Group I (Figs. 10.9 D) at a difference of 5% w/w of oil.

Group II (Fig. 10.10 E) S_{mix} ratio (S:CoS) 3:1 Formulations	Percentage w/w of different components in formulation		Observations based on the preparation, thermodynamic stability studies and dispersibility tests				Inference
	Oil	S_{mix}	H/C	Cent.	Freez. Tha.	Disperse.	
F_1	20	80	√	√	√	Grade A	Selected
F_2	25	75	√	√	√	Grade B	Selected
F_3	30	70	√	√	√	Grade C	Selected
F_4	35	65	√	√	√	Grade D	Rejected
F_5	40	60	√	√	√	Grade D	Rejected
F_6	45	55	√	√	√	Grade E	Rejected
F_7	50	50	√	√	√	Grade E	Rejected

Where, Heating cooling cycle (H/C).

Freeze-thaw cycle (Freez. Tha.).

Centrifugation (Cent.).
Dispersibility test (Disperse.)

Table 3.6: Data for Thermodynamic stability test of different formulations selected from Group II (Figs. 10.9 E) at a difference of 5% w/w of oil.

Group II (Fig. 10.10 E) S_{mix} ratio (S:CoS) 3:1	Percentage w/w of different components in formulation		Observations based on the preparation, thermodynamic stability studies and dispersibility tests				Inference
	Oil	S_{mix}	H/C	Cent.	Freez. Tha.	Disperse.	
F ₁	20	80	√	√	√	Grade A	Selected
F ₂	25	75	√	√	√	Grade B	Selected
F ₃	30	70	√	√	√	Grade C	Selected
F ₄	35	65	√	√	√	Grade D	Rejected
F ₅	40	60	√	√	√	Grade D	Rejected
F ₆	45	55	√	√	√	Grade E	Rejected
F ₇	50	50	√	√	√	Grade E	Rejected

Where, Heating cooling cycle (H/C).

Freeze-thaw cycle (Freez. Tha.).

Centrifugation (Cent.).

Dispersibility test (Disperse.)

3.5. Preparation of Liquid SEDDS Formulations

Formulations selected in section 10.6 were prepared as per the composition reported in **Table 2.1** and found to be thermodynamically stable even after addition of a drug.

3.6. Evaluation of Liquid SEDDS Formulations

3.6.1. Determination of emulsification time

In SEDDS, the primary means of self-emulsification process is visual evaluation. The efficiency of self-emulsification could be estimated by determining the rate of emulsification. The rate of emulsification is an important index for the assessment of the efficiency of emulsification that is the SEDDS should disperse completely and quickly when subjected to aqueous dilution under mild agitation. The emulsification time of liquid SEDDS are presented in **Table 3.7**. Emulsification time study showed that all the formulations emulsified within 20 s. Among the tested formulations, formulations A and D showed shortest emulsification time than others.^[26]

3.6.2. Turbidimetric evaluation^[21]

The results of turbidimetric evaluation of liquid SEDDS are presented in **Table 3.7**. Formulations A and D showed low turbidity values (23.1 NTU and 31 NTU, respectively) owing to the presence of adequate amounts of surfactant (Tween 20), which primarily governs the resultant droplet size and its distribution. Formulation C and F, with moderate quality of emulsion formation

because of high concentration of oil and showed very high and variable turbidity (94.2 ± 15.8 NTU and 82.1 ± 12.8 , mean \pm SD, $n = 3$) and coarser droplets. Formulation B and E showed moderate turbidity values (41.1 NTU and 31.7 NTU, respectively).

Thus the droplet size distribution is strongly dependent on concentration of surfactant/co-surfactant.

3.6.3. Drug Content

The drug content of all formulations ranged between 5.79 and 7.95 mg/mL (**Table 3.7.**) and passed uniformity of content.

3.6.4. Globule size analysis

Droplet size of SMEDDS is a critical parameter in the adapted strategy of enhancing drug bioavailability. Droplet size analysis revealed the effect of varying amounts of Tween 20 and PEG 400 in the formulated SEDDS. Changes in Tween 20 to PEG 400 ratios are most likely to alter the resultant HLB of the system and the properties of liquid crystal (LC) interfaces. This in turn governs the size of droplets formed. Thus it is the appropriate choice of surfactant and co-surfactant together with their proper concentrations, which provides an optimum self-emulsifying formulation. The mean droplet sizes of the reconstituted microemulsions are reported in **Table 3.7**. As shown in the table, the average droplet sizes of all microemulsions were less than 700 nm.^[26,27]

Table 3.7: Data for Evaluation of Liquid SEDDS formulations.

Evaluation Parameters	Group I (S_{mix} 2:1)			Group II (S_{mix} 3:1)		
	A	B	C	D	E	F
Emulsification Time (S) ^a	12 \pm 2	17 \pm 3	19 \pm 4	14 \pm 3	16 \pm 2	18 \pm 1
Turbidity (NTU) ^a	23.1 \pm 2.28	41.1 \pm 3.41	94.2 \pm 15.8	31 \pm 4.76	31.7 \pm 2.7	82.1 \pm 12.8
Drug Content (mg/ml) ^a	5.79 \pm 0.05	7.95 \pm 0.043	7.11 \pm 0.067	6.38 \pm 0.9	6.29 \pm 0.02	7.87 \pm 0.11
Mean Droplet Size (μ m)	0.306	0.518	0.690	0.315	0.348	0.366

^aMean ± SD, n = 3.

3.6.5. Drug release studies^[13]

The *in-vitro* drug release study of liquid SEDDS were performed in 0.1N HCl. The percent drug release for different formulations is shown in **Table 3.8**. In the self-emulsifying systems, the free energy required to form an emulsion was very low, thereby allowing spontaneous formation of an interface between the oil droplets and water. It is suggested that the oil/surfactant/co-surfactant and water phases effectively swell and eventually there was increase the release rate. It was clear from the

Figure 3.6 and 3.7. The maximum percentage of the drug released within 5min because of fast emulsification. The SEDDS represented Amlodipine in solubilized form in gastric fluids after ingestion and hence provided large interfacial area for Amlodipine absorption.

Therefore, the optimized formulations (C and F), had higher drug release than marketed preparation, optimum globule size, and stability of emulsion and drug and above all, lower surfactant concentration was selected for the further study.

Table 3.8: Dissolution data for Liquid SEDDS formulations in 0.1N HCl.

Time (Minute)	*Percent drug dissolved					
	A	B	C	D	E	F
0	0.000	0.000	0.000	0.000	0.000	0.000
05	94.667±1.25	96.098±0.65	96.865±1.33	97.584±1.25	94.548±1.12	96.597±1.78
15	90.927±1.57	96.272±0.59	97.486±1.4	96.648±1.45	94.475±1.36	96.954±1.05
30	91.451±2.45	96.327±1.01	97.991±2.76	96.487±1.54	94.594±1.55	96.485±1.19
60	91.976±2.68	96.320±1.3	98.458±2.06	96.123±1.68	94.635±1.48	96.895±1.45

*Represents mean ± S.D. (n = 3),




Figure 3.6:- *In-vitro* drug release profile of Liquid SEDDS Formulations, A, B, C in 0.1N HCl.




Figure 3.7: *In-vitro* drug release profile of Liquid SEDDS Formulations D, E, F in 0.1N HCl.

3.7. Preparation of Solid SEDDS

Solid SEDDS were prepared as per the composition reported in **Table 2.3**.

3.8. Evaluation of Solid SEDDS Formulations

3.8.1. Reconstitution properties of solid SEDDS^[16]

The mean droplet sizes of the solid SEDDS is presented in **Table 3.9**. As shown in the table, the z-average droplet sizes of both systems were less than 1µm. The droplet size of the emulsion from the solid SEDDS was slightly increased, compared to the liquid SMEDDS. At the same time, a broader size distribution was observed.

The solid SEDDS preserved the self-emulsification performance of the liquid SEDDS.

Table 3.9: Data for Evaluation of Solid SEDDS formulations.

Evaluation Parameters	Group I (S _{mix} 2:1)	Group II (S _{mix} 3:1)
	F ₁	F ₂
Emulsification Time (S) ^a	20±2	15±3
Drug Content (% w/w) ^a	2.59±0.85	2.52±0.48
Mean Droplet Size (µm)	0.839	0.623

^aRepresents mean ± S.D. (n = 3)

3.8.2. Drug Content

The drug content of both formulations ranged between 2.50 and 2.60 % w/w (**Table 3.9**).

3.8.3. Drug release study

The *in-vitro* drug release studies were performed in order to ensure the quick release of the drug in the dissolution medium. *In-vitro* dissolution studies also give an idea about the self-emulsification efficiency of the developed system. The *in-vitro* drug release profile of F₁ and F₂ was

evaluated in 0.1N HCl (n = 3). It was observed that both the solid SEDDS formulations F₁ and F₂ released more than 90% of Amlodipine within 60 min. Both the formulations dispersed almost instantaneously indicating the high self-emulsion efficiency of the developed formulations.

The graphs of the drug release profile are shown in **Figure 3.8**. Amlodipine from the solid SEDDS was completely and rapidly dissolved in medium without affecting the dissolution pattern also.

Table 3.10: Dissolution data for formulations in 0.1N HCl.

Time (Minute)	*Percent drug dissolved	
	F ₁	F ₂
0	0.000	0.000
05	88.419±1.06	91.338±1.80
15	89.201±2.60	91.898±3.95
30	89.906±1.10	92.497±1.71
60	91.041±2.96	93.059±1.53

Represents mean ± S.D. (n = 3)




Figure 3.8:- In- vitro drug release profile of Solid SEDDS Formulations F₁ and F₂.

3.8.4. Morphological analysis of solid SEDDS

The outer macroscopic morphology of the Solid SEDDS revealed well separated spherical particle with smooth surface seen in SEM images of the Solid SEDDS. **Figure 3.9** shows the scanning electron micrographs of the Maltodextrin powder and Solid SEDDS formulation. Maltodextrin (**Figure 3.9 A and 3.9 B**) appeared with a rough surface with porous particles. However, the solid SEDDS (**Figure 3.9 C and 3.9 D**) appeared as smooth-surfaced Maltodextrin particles, indicating that the liquid SEDDS is adsorbed or embedding inside the pores of Maltodextrin. Following spray-drying, maltodextrin is known to produce deep and abundant surface dents and the limited agglomeration of particles was probably due to maltodextrin ability to diminish the degree of particle agglomeration and to the storage of products in closed vials protected from humidity; hence preferred as carrier in the study.^[28,29]




Figure 3.9: Scanning electron micrographs: (A & B) Maltodextrin; (C & D) Solid SEDDS.

3.8.5. Solid state characterization of solid SEDDS

3.8.5.1. DSC

The physical state of amlodipine in the solid SEDDS was investigated since it would have an important influence on the *in-vitro* and *in-vivo* release characteristics. DSC curves of pure amlodipine, and the solid SEDDS of amlodipine are shown in **Figure 3.10**. Pure amlodipine

showed three sharp endothermic peaks at temperatures between 205^o and 210^oC. No obvious peaks for amlodipine and oil were found in the solid SEDDS of amlodipine. It might be explained that the melting behavior of the oil was changed by maltodextrin and the crystallization of amlodipine was inhibited by maltodextrin and surfactants.^[29]




Figure 3.10:- DSC Spectra of pure Amlodipine and Solid SEDDS.

3.9. Photostability study

The photostability studies of pure amlodipine and Solid SEDDS were done by exposing these samples to the fluorescent light using photostability chamber (21CFR, Newtronic megalis). The Samples were assayed for their content of amlodipine prior to exposure and at 4, 8, 12, and 24 h of continuous exposure using HPLC assay method. The decomposition of pure amlodipine was found to be remarkable upon exposure to fluorescent lamp or sunlight (which is the main source of light during manufacturing, storage and handling). The retention time for amlodipine and its degradation product was found to be 3.3 ± 0.18 and 2.9 ± 0.14 respectively.

In this study, Solid SEDDS was prepared by spray drying the Liquid SEDDS with relatively excess amount of maltodextrin compared to amlodipine. The outer macroscopic morphology of the Solid SEDDS observed by SEM (**Figure 3.9 C & 3.9 D**) suggests that most of the amlodipine was encapsulated in the maltodextrin matrix. Therefore the improved photostability of Solid SEDDS might be due to the compact physical barrier composed of maltodextrin as observed as the smooth

surface of the Solid SEDDS powder (**Figure 3.9 C & 3.9 D**).^[30]

This study indicated that the rate of photo degradation is very slow in Solid SEDDS as compared to pure amlodipine powder; thus Solid SEDDS conferred photostability to drug.




Figure 3.11: Chromatograms of Amlodipine Solid SEDDS at different time interval.




Figure 3.12: Chromatograms of Pure Amlodipine at different time interval.

4. CONCLUSION

- In the present investigation, Solid self-emulsifying drug delivery systems of amlodipine were prepared and evaluated for its *in vitro* performance.
- Optimized, Solid amlodipine SEDD system composed of amlodipine (5 mg), Labrafil M 1944 CS (30%), S_{mix} (70%) and Maltodextrin (10 gm).
- The globule size distribution of this formulation was within appropriate range (0.600–0.900 μm).
- *In vitro* release in 0.1 N HCl revealed a prompt release within 5 minute up to 90%. SEDDS of amlodipine showed a significant increase in release rate.
- Amlodipine was protected from light by its incorporation in Solid SEDDS. Such matrices

prevent drug oxidation to the aromatic derivative through a number of chemical and physical barriers. The system under investigation had shown a high degree of photostability when compared with plain drug.

- Then from results reported it can be concluded that the prepared Solid SEDD system served as possible alternative to overcome the problems associated with conventional oral drug delivery system of Amlodipine.

12. REFERENCES

1. Tonnesen H. Photostability of Drugs and Drug Formulations. Second Edition. CRC PRESS Boca Raton London New York Washington. 2004; 1-7.
2. Vries D, Beijersbergen H, Henegouwen V, Huf, FA. Photochemical decomposition of chloramphenicol in a 0.25% eyedrop and in a therapeutic intraocular concentration. *Int. J. Pharm.* 1984; 20: 265-271.
3. Valenzano DP, Pottier RH, Mathis P, Douglas RH. Photobiological Techniques. London: Plenum Press. 1991; 85-120, 165-178, 347-349.
4. Oppenländer T. A comprehensive photochemical and photophysical assay exploring the photoreactivity of drugs. *CHIMIA.* 1988; 42: 331-342.
5. Greenhill JV, McLelland MA. Photodecomposition of drugs in Ellis, G.P. and West, G.B. (Eds.), *Progress in Medicinal Chemistry.* 1990; 51-121.
6. Nema S, Washkuhn RJ, Beussink DR. Photostability testing: an overview. *Pharm. Tech.* 1995; 19: 170.
7. Matsuda Y, Minamida Y. Stability of solid dosage forms. II. Coloration and photolytic degradation of sulfisomidine tablets by exaggerated ultraviolet irradiation. *Chem. Pharm. Bull.* 1976; 24: 2229-2236.
8. Aman W, Thoma K. Photostabilisation of tablets by blister covers. *Pharm. Ind.* 2002; 64: 1287-1292.
9. B'échard SR, Quraichi O, Kwong E. Film coating effect of titanium dioxide concentration and film thickness on the photostability of nifedipine. *Int. J. Pharm.* 1992; 87: 133-139.
10. Crowley PJ. Excipients as stabilizers. *Pharm. Sci. Technol. Today* 1999; 2:237-243.
11. C'ordoba-Borrego M, C'ordoba-D'ia'z M, C'ordoba-D'ia'z D. Validation of a high-performance liquid chromatographic method for the determination of norfloxacin and its application to stability studies. *J. Pharm. Biomed. Anal.* 1999; 18: 919-926.
12. Slaveska R, Balint L, Momirovic-Culjat J, Spirevska I. Study of inhibitory effect of cysteine and cysteamine on reaction of adrenaline oxidation in presence of EDTA and superoxide dismutase. *Acta Pharm.* 1995; 45: 503-509.
13. Evans RK, Bohannon KE, Wang B, Volkin DB. Evaluation of degradation pathways for plasmid DNA in pharmaceutical formulations via accelerated stability studies. *J. Pharm. Sci.* 2000; 89: 76-87.
14. Matsuda Y, Tatsumi E. Physicochemical characterization of furosemide modifications. *Int. J. Pharm.* 1990; 60: 11-26.
15. Kumar N, Windisch V, Ammon H L. Photoinstability of some tyrophostin drugs: chemical consequences of crystallinity. *Pharm. Res.* 1995; 12: 1708-1715.
16. De Villiers MM, Vanderwatt JG, L'otter AP. Kinetic study of the solid state photolytic degradation of two polymorphic forms of furosemide. *Int. J. Pharm.* 1992; 88: 275-283.
17. Teraoka R, Otsuka M, Matsuda Y. Evaluation of photostability of solid-state nifedipine hydrochloride polymorphs by using Fourier-transformed reflection-absorption infrared spectroscopy-effect of grinding on the photostability of crystal form. *Int. J. Pharm.* 2004; 286: 1-8.
18. Kitamura S, Miyamae A, Koda S, Morimoto Y. Effect of grinding on the solid-state stability of cefixime trihydrate. *Int. J. Pharm.* 1989; 56: 125-134.
19. Teraoka R, Otsuka M, Matsuda Y. Evaluation of photostability of solid state dimethyl-1,4-dihydro-2,6-dimethyl-4-(2-nitro-phenyl)-3,5-pyridinedicarboxylate by using Fourier-transformed reflection-absorption infrared spectroscopy. *Int. J. Pharm.* 1999; 184: 35-43.
20. De Villiers MM, Vanderwatt JG, L'otter AP. Influence of the cohesive behaviour of small particles on the solid-state photolytic degradation of furosemide. *Drug Dev. Ind. Pharm.* 1993; 19:383-394.
21. L'obenberg R, Amidon GL. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. *Eur. J. Pharm. Biopharm.* 2000; 50: 3-12.
22. Tarr BD, Yalkowsky SH. Enhancement intestinal absorption of cyclosporine in rats through the reduction of emulsion droplet size. *Pharm. Res.* 1989; 6: 40-43.
23. Welin-Berger K, Bergenst ° ahl B. Inhibition of Ostwald ripening in local anesthetic emulsions by using hydrophobic excipients in the disperse phase. *Int. J. Pharm.* 2000; 200: 249-260.
24. Vyas SP, Jain CP, Kaushik A, Dixit VK. Preparation and characterisation of griseofulvin dry emulsion. *Pharmazie* 1992; 47: 463-464.
25. Dollo G, Le Corre P, Guerin A, Chevanne F, Burgot JL, Leverage R. Spray-dried redispersible oil-in-water emulsion to improve oral bioavailability of poorly soluble drugs. *Eur. J. Pharm. Sci.* 2003; 19: 273-280.
26. Takeuchi H, Sasaki H, Niwa T, Hino T, Kawashima Y, Uesugi K, Ozawa H. Improvement of photostability of ubidecarenone in the formulation of a novel powdered dosage form termed redispersible dry emulsion. *Int. J. Pharm.* 1992; 86: 25-33.
27. Heinzelmann K, Franke K. Using freezing and drying techniques of emulsions for the microencapsulation of fish oil to improve oxidation stability. *Colloids Surf. B* 1999; 12: 223-229.
28. Myers SL, Shively ML. Preparation and characterization of emulsifiable glasses: oil-in-water and water-in-oil -in- water emulsions. *J. Colloid Interface Sci.* 1992; 149: 271-278.
29. Molina C, Cadorniga R. Physical stability of lyophilized and sterilized emulsions. *S.T.P. Pharma Pratiques* 1995; 5: 63-72.

30. Robinson JR. Introduction: Semi-solid formulations for oral drug delivery. *B T Gattefosse*. 1996; 89: 11–3.
31. Amidon GL, Lennernas H, ShahVP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. *Pharm Res*. 1995; 12: 413–20.
32. Wadke DA, Serajuddin AM, Jacobson H. Preformulation testing. In: Lieberman HA, Lachman L, Schwartz JB, editors. *Pharmaceutical Dosage Forms: Tablets, 1*. NewYork: Marcel Dekker.1989; 1–73.
33. Serajuddin AM. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems and recent breakthroughs. *J Pharm Sci*. 1999; 88:1058–66.
34. Aungst BJ. Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism. *J Pharm Sci.*, 1993; 82: 979–86.
35. Burcham DL, Maurin MB, Hausner EA, Huang SM. Improved oral bioavailability of the hypocholesterolemic DMP 565 in dogs following oral dosing in oil and glycol solutions. *Biopharm Drug Dispos* 1997; 18: 737–42.
36. Serajuddin AM, Shee PC, Mufson D, Bernstein DF, Augustine MA. Effect of vehicle amphiphilicity on the dissolution and bioavailability of a poorly water-soluble drug from solid dispersion. *J Pharm Sci*. 1988; 77: 414–7.
37. Aungst BJ, Nguyen N, Rogers NJ, Rowe S, Hussain M, Shum L, White S. Improved oral bioavailability of an HIV protease inhibitor using Gelucire 44/14 and Labrasol vehicles. *B T Gattefosse*. 1994; 87: 49–54.
38. Wakerly MG, Pouton CW, Meakin BJ, Morton FS. Self emulsification of vegetable oil-non-ionic surfactant mixtures. *ACS Symp Series* 1986; 311: 242–55.
39. Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs *Biomedicine & Pharmacotherapy* 2004; 58: 173–182.
40. Shah NH, Carvajal MT, Patel CI, Infeld MH, Malick AW. Selfemulsifying drug delivery systems (SEDDS) with polyglycolized glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. *Int J Pharm*. 1994; 106: 15–23.
41. Craig DM, Lievens HR, Pitt KG, Storey DE. An investigation into the physicochemical properties of self-emulsifying systems using low frequency dielectric spectroscopy, surface tension measurements and particle size analysis. *Int J Pharm*. 1993; 96: 147–55.
42. Toguchi H, OgawaY, Iga K, Yashiki T, Shimamoto T. Gastrointestinal absorption of ethyl 2-chloro-3-(4-(2-methyl-2-phenylpropyloxy) phenyl)propionate from different dosage forms in rats and dogs. *Chem Pharm Bull*. 1990; 38: 2792–6.
43. Palin KJ, Phillips AJ, Ning A. The oral absorption of cefoxitin from oil and emulsion vehicles in rats. *Int J Pharm* 1986; 33: 99–104.
44. Myers RA, Stella VJ. Systemic bioavailability of penclomedine (NSC–338720) from oil-in-water emulsions administered intraduodenally to rats. *Int J Pharm*. 1992; 78: 217–26.
45. Stella VJ, Haslam J, Yata N, Okada H, Lindenbaum S, Higuchi T. Enhancement of bioavailability of a hydrophobic amine antimalarial by formulation with oleic acid in a soft gelatin capsule. *J Pharm Sci*. 1978; 67: 1375–7.
46. Kararli TT, Needham TE, Griffin M, Schoenhard G, Ferro LJ, Alcorn L. Oral delivery of a renin inhibitor compound using emulsion formulations. *Pharm Res*. 1992; 9: 888–93.
47. Schwendener RA, Schott H. Lipophilic 1-beta-D-arabinofuranosyl cytosine derivatives in liposomal formulations for oral and parenteral antileukemic therapy in the murine L1210 leukemia model. *J Cancer Res Clin Oncol*. 1996; 122: 723–6.
48. Constantinides PP. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. *Pharm Res*. 1995; 12: 1561–72.
49. Craig DM. The use of self-emulsifying systems as a means of improving drug delivery. *B T Gattefosse*. 1993; 86: 21–31.
50. Bhosale AV, Patel PA. Self Emulsifying Drug Delivery System: A Review Research *J. Pharm. and Tech*. Oct.-Dec. 2008; 1(4): 313-323.
51. Wakerly MG, Pouton CW, Meakin BJ. Evaluation of the self emulsifying performance of a non-ionic surfactant–vegetable oil mixture. *J Pharm Pharmacol*. 1987; 39: 6.
52. Pouton CW. Effects of the inclusion of a model drug on the performance of self-emulsifying formulations. *J Pharm Pharmacol* 1985; 37: 1.
53. Chanana GD, Sheth BB. Particle size reduction of emulsions by formulation design. II: effect of oil and surfactant concentration. *PDA J Pharm Sci Technol*. 1995; 49: 71–6.
54. Kimura M, Shizuki M, Miyoshi K, Sakai T, Hidaka H, Takamura H, Matoba T. Relationship between the molecular structures and emulsification properties of edible oils. *Biosci Biotech Biochem*. 1994; 58: 1258–61.
55. Hauss DJ, Fogal SE, Ficorilli JV, Price CA, Roy T, Jayaraj AA, Keirns JJ. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorlywater-soluble LTB4 inhibitor. *J Pharm Sci*. 1998; 87: 164–9.
56. Karim A, Gokhale R, Cole M, Sherman J, Yeramian P, Bryant M, Franke H. HIV protease inhibitor SC-52151: a novel method of optimizing bioavailability profile via a microemulsion drug delivery system. *Pharm Res*. 1994; 11: S368.
57. Gershanik T, Benita S. Self-dispersing lipid formulations for improving oral absorption of

- lipophilic drugs. *Eur J Pharm Biopharm.* 2000; 50:179–88.
58. Lindmark T, Nikkila T, Artursson P. Mechanisms of absorption enhancement by medium chain fatty acids in intestinal epithelial Caco-2 monolayers. *J Pharmacol Exp Ther.* 1995; 275: 958–64.
59. Charman WN, Stella VJ. Transport of lipophilic molecules by the intestinal lymphatic system. *Adv Drug Del Rev.* 1991; 7: 1–14.
60. Holm R, Porter CJH, Müllertz A, Kristensen HG, Charman WN. Structured triglyceride vehicles for oral delivery of halofantrine: examination of intestinal lymphatic transport and bioavailability in conscious rats. *Pharm Res.* 2002; 19: 1354–61.
61. Yuasa H, Sekiya M, Ozeki S, Watanabe J. Evaluation of milk fat globule membrane (MFGM) emulsion for oral administration: absorption of α -linolenic acid in rats and the effect of emulsion droplet size. *Biol Pharm Bull* 1994; 17:756–8.
62. Georgakopoulos E, Farah N, Vergnault G. Oral anhydrous non-ionic microemulsions administered in softgel capsules. *B T Gattefosse.* 1992; 85: 11–20.
63. Swenson ES, Milisen WB, Curatolo W. Intestinal permeability enhancement: efficacy, acute local toxicity and reversibility. *Pharm Res.* 1994; 11: 1132–42.
64. Meinzer A, Mueller E, Vonderscher J. Microemulsion – a suitable galenical approach for the absorption enhancement of low soluble compounds. *B T Gattefosse.* 1995; 88: 21–6.
65. Vondercher J, Meizner A. Rationale for the development of Sandimmune Neoral. *Transplant Proc.* 1994; 26: 2925–7.
66. Levy MY, Benita S. Drug release from submicronized o/w emulsion: a new in vitro kinetic evaluation model. *Int J Pharm.* 1990; 66: 29–37.
67. Craig DM, Barker SA, Banning D, Booth SW. An investigation into the mechanisms of self-emulsification using particle size analysis and low frequency dielectric spectroscopy. *Int J Pharm.* 1995; 114: 103–10.
68. Kommuru TR, Gurley B, Khan MA, Reddy IK. Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment. *Int J Pharm.* 2001; 212: 233–46.
69. Pouton CW. Formulation of self-emulsifying drug delivery systems. *Adv Drug Del Rev.* 1997; 25:47–58.
70. Pouton CW. Self-emulsifying drug delivery systems: assessment of the efficiency of emulsification. *Int J Pharm.* 1985; 27: 335–48.
71. Westesen K, Koch MJ. Phase diagram of tyloxapol and water–II. *Int J Pharm.* 1994; 103: 225–36.
72. Reiss H. Entropy-induced dispersion of bulk liquids. *J Colloids Interface Sci.* 1975; 53: 61–70.
73. Dabros T, Yeung A, Masliyah J, Czarnecki J. Emulsification through area contraction. *J Colloids Interface Sci.* 1999; 210: 222–4.
74. Attama AA, Mpamaugo VE. Pharmacodynamics of piroxicam from self-emulsifying lipospheres formulated with homolipids extracted from *Capra hircus*. *Drug. Deliv.* 2006; 13: 133–137.
75. Jannin V. Approaches for the development of solid and semi-solid lipid-based formulations. *Adv. Drug. Deliv. Rev.* 2008; 60: 734–746.
76. Dong L. A novel osmotic delivery system: L-OROS SOFTCAP. Proceedings of the International Symposium on Controlled Release of Bioactive Materials. Paris (CD ROM) July 2000.
77. Dong L. L-OROS HARDCAP: a new osmotic delivery system for controlled release of liquid formulation. Proceedings of the International Symposium on Controlled Release of Bioactive Materials. San Diego. June 2001.
78. Cole ET. Challenges and opportunities in the encapsulation of liquid and semi-solid formulations into capsules for oral administration. *Adv. Drug. Deliv. Rev.* 2008; 60: 747–756.
79. Ito Y. Oral solid gentamicin preparation using emulsifier and adsorbent. *J. Control Release.* 2005; 105: 23–31.
80. Fabio C, Elisabetta C. Pharmaceutical composition comprising a water/oil/water double microemulsion incorporated in a solid support. WO2003/013421.
81. Boltri L. Enhancement and modification of etoposide release from crospovidone particles loaded with oil-surfactant blends. *Pharm. Dev. Technol.* 1997; 2: 373–381.
82. Venkatesan N. Liquid filled nanoparticles as a drug delivery tool for protein therapeutics. *Biomaterials.* 2005; 26: 7154–7163.
83. Seo A. The preparation of agglomerates containing solid dispersions of diazepam by melt agglomeration in a high shear mixer. *Int. J. Pharm.* 2003; 259: 161–171.
84. Gupta MK. Enhanced drug dissolution and bulk properties of solid dispersions granulated with a surface adsorbent. *Pharm. Dev. Technol.* 2001; 6: 563–572.
85. Gupta MK. Hydrogen bonding with adsorbent during storage governs drug dissolution from solid-dispersion granules. *Pharm. Res.* 2002; 19: 1663–1672.
86. Verreck G, Brewster ME. Melt extrusion-based dosage forms: excipients and processing conditions for pharmaceutical formulations. *Bull. Tech. Gattefosse.* 2004; 97: 85–95.
87. Newton M. The influence of formulation variables on the properties of pellets containing a self-emulsifying mixture. *J. Pharm. Sci.* 2001; 90: 987–995.
88. Newtonn JM. Formulation variables on pellets containing self emulsifying systems. *Pharm. Tech. Eur.* 2005; 17: 29–33.
89. Newton JM. The rheological properties of self-emulsifying systems, water and microcrystalline cellulose. *Eur. J. Pharm. Sci.* 2005; 26: 176–183.

90. Tuleu C. Comparative bioavailability study in dogs of a self-emulsifying formulation of progesterone presented in a pellet and liquid form compared with an aqueous suspension of progesterone. *J. Pharm. Sci.* 2004; 93: 1495–1502.
91. Iosio T. Bi-layered self-emulsifying pellets prepared by co-extrusion and spheronization: influence of formulation variables and preliminary study on the in vivo absorption. *Eur. J. Pharm. Biopharm.* 2008; 10: 1016.
92. Groves MJ, Mustafa RA, Carless JE. Phase studies of mixed phosphate surfactants, n-hexane and water. *J Pharm Pharmacol.* 1974; 26: 616–23.
93. Rang MJ, Miller CA. Spontaneous emulsification of oils containing hydrocarbon, non-ionic surfactant, and oleyl alcohol. *J Colloids Interface Sci.* 1999; 209: 179–92.
94. Pouton CW, Wakerly MG, Meakin BJ. Self-emulsifying systems for oral delivery of drugs. *Proc Int Symp Control Release Bioact Mater.* 1987; 14: 113–4.
95. Gursoy N, Garrigue JS, Razafindratsita A, Lambert G, Benita S. Excipient effects on in vitro cytotoxicity of a novel paclitaxel self emulsifying drug delivery system. *J Pharm Sci.* 2003; 92: 2420–7.
96. Singh S, Chakraborty S, Shukla D, Mishra B. Lipid – An emerging platform for oral delivery of drugs with poor bioavailability. *European Journal of Pharmaceutics and Biopharmaceutics.* 2009; 73: 1–15.
97. Caitriona M. O’Driscoll Lipid-based formulations for intestinal lymphatic delivery. *European Journal of Pharmaceutics and Biopharmaceutics.* 2002; 15: 405–415.
98. Takeuchi H, Sasaki H, Niwa T, Hino T, Kawashima Y, Uesugi K, Ozawa H. Improvement of Photostability of ubidecarenone in the formulation of a novel powdered dosage form termed redispersible dry emulsion. *Int. J. Pharm.* 1992; 86:25–33.
99. Charman WN, Shui-Mei K. Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine. *International Journal of Pharmaceutics.* 1998; 167: 155–164.
100. Ragno G. Photodegradation monitoring of amlodipine by derivative spectrophotometry, *Journal of Pharmaceutical and Biomedical Analysis.* 2002; 27: 19–24.
101. Bayomi MA. Effect of inclusion complexation with cyclodextrins on photostability of nifedipine in solid state. *International Journal of Pharmaceutics.* 2002; 243: 107–117.
102. Ragno G. Design and monitoring of photostability systems for amlodipine dosage forms. *International Journal of Pharmaceutics.* 2003; 265: 125–132.
103. Fasani E. Mechanism of the photochemical degradation of amlodipine. *International Journal of Pharmaceutics.* 2008; 352: 197–201.
104. Feng N. Preparation and evaluation of self-microemulsifying drug delivery system of oridonin. *International Journal of Pharmaceutics.* 2008; 355: 269–276.
105. Nagarsenker MS, Dixit RP. Self-nanoemulsifying granules of ezetimibe: Design, optimization and evaluation. *European journal of pharmaceutical sciences.* 2008; 35: 183–192.
106. Yang X. A new solid self-microemulsifying formulation prepared by spray-drying to improve the oral bioavailability of poorly water soluble drugs. *European journal of pharmaceutical sciences.* 2008; 70: 439-444.
107. Kumar D. Investigation of a nanoemulsion as vehicle for transdermal delivery of amlodipine. *Die Pharmazie.* 2009; 64: 80-85.
108. Balakrishnan P. Enhanced oral bioavailability of Coenzyme Q10 by self-emulsifying drug delivery systems *International Journal of Pharmaceutics* 374, 2009; 66–72.
109. Yong CS, Balakrishnan P. Enhanced oral bioavailability of dexibuprofen by a novel solid Self-emulsifying drug delivery system (SEDDS). *European Journal of Pharmaceutics and Biopharmaceutics.* 2009; 72: 539–545.
110. Wang Z. Solid self-emulsifying nitrendipine pellets: Preparation and in vitro/in vivo Evaluation. *International Journal of Pharmaceutics.* 2010; 383: 1–6.
111. Gupta AK. Preparation and in-vitro evaluation of self emulsifying drug delivery system of antihypertensive drug valsartan, *International Journal of Pharmacy and life sciences.* 2011; 2(3).
112. Pal VK. Self Emulsifying Drug Delivery System, *Journal of Pharmaceutical Research and Opinoin.* 2011; 80-84.
113. Vavia P. Design and Evaluation of Lumefantrine-Oleic acid Self nanoemulsifying ionic complex for enhanced dissolution. 2013; 21: 27.
114. Usha Sri B. Enhancement of Solubility and Oral Bioavailability of Poorly Soluble drug Valsartan by Novel Solid Self Emulsifying Drug Delivery System, *International Journal of Drug Delivery.* 2015; 13-26.
115. Humphreys A, Boersig C. Cholesterol drugs dominate. *Med. Ad. News.* 2003; 22: 42–57.
116. Mohsen AB. Effect of inclusion complexation with cyclodextrins on photostability of nifedipine in solid state. *International Journal of Pharmaceutics.* 2002; 243: 107–117.
117. Ragno G. Design and monitoring of photostability systems for amlodipine dosage forms. *International Journal of Pharmaceutics.* 2003; 265: 125–132.
118. Patravale VB. Development of SMEDDS using natural lipophile: Application to β - Artemether delivery, *International Journal of Pharmaceutics.* 2008; 362: 179–183.
119. Indian pharmacopoeia. Government of India, ministry of health and family welfare’s, published by the controller of publications, The Indian

- pharmacopoeia commission Ghaziabad. Vol-1 and Vol-2, 2007. pp 714-715.
120. Goodman, Gilman. The pharmacological Basis of Therapeutics. 10: pp853-860.
121. Dollery C. Therapeutics drug. New York: Cornell University Press. Volume -I, 2000; 1:pp A151-A154.
122. Raymond CR., Paul J. Handbook of Pharmaceutical excipients. Alpha pharmaceutical, London, Chicago. 2006; 5: Pp.535-538, 1158-1164, 1446-1464.
123. www.gatefosse.com/ LABRAFIL® M 1944 CS.
124. Date AA, Nagarsenker MS. Design and evaluation of self-nanoemulsifying drug delivery systems (SNEDDS) for cefpodoxime proxetil. Int. J. Pharm. 2007; 329: 166–172.
125. Bachynsky MO, Shah NH, Patel CI, Malick AW. Factors affecting the efficiency of self-emulsifying oral delivery system. Drug Dev. Ind. Pharm. 1997; 23: 809–816.
126. Paradkar A, Patil P, Patil V. Formulation of a self-emulsifying system for oral delivery of simvastatin: *In vitro* and *in vivo* evaluation. Acta Pharm. 2007; 57: 111–122.
127. Yeung PK, Mosher SJ, Pollak PT. Liquid chromatography assay for amlodipine: chemical stability and pharmacokinetics in rabbits. J. Pharm. Biomed. Anal. 1991; 7: 565–57.
128. Mohammadi A, Rezanour N. A stability-indicating high performance liquid chromatographic (HPLC) assay for the simultaneous determination of atorvastatin and amlodipine in commercial tablets, Journal of Chromatography B., 2007; 846: 215-21.
129. Pouton CW. Formulation of self-emulsifying drug delivery systems. Adv. Drug Del. Rev., 1997; 25: 47–58.
130. Benita S, Neslihan R. Drug delivery and drug efficacy, Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs, Biomedicine & Pharmacotherapy. 2004; 58: 173–182.
131. Pouton CW, Porter C.H. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. Adv. Drug Deliv. Rev. 2008; 60: 625–637.
132. Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems, Adv. Drug Deliv. Rev. 2000; 45: 89–121.
133. Craig DQ, Barker SA, Banning D, Booth SW. An investigation into the Mechanisms \ of self-emulsification using particle size analysis and low frequency dielectric spectroscopy. Int. J. Pharm. 1995; 114: 103–110.
134. Yosra SR, El-Massik M, Ossama Y. Self-nanoemulsifying drug delivery systems of tamoxifen citrate: Design and optimization, International Journal of Pharmaceutics. 2009; 380: 133–141.
135. Gilles Dollo, Pascal Le Corre, et al., Spray-dried redispersible oil-in-water emulsion to improve oral bioavailability of poorly soluble drugs, European Journal of Pharmaceutical Sciences. 2003;19: 273–280.
136. Pedersen GP, Faldt P, Bergenstahl B, Kristensen HG. Solid state characterization of a dry emulsion: a potential drug delivery system, Int. J. Pharm. 1998; 171: 257–270.
137. Kim CK, Jang DJ. Improvement of bioavailability and photostability of amlodipine using redispersible dry emulsion, European journal of pharmaceutical sciences. 2006; 28: 405-11.